首页> 外文OA文献 >Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

【2h】

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

机译：I阶段I研究CBP501，A G2 Checkpoint Abrogator，作为单药治疗，以及与先进实体瘤患者的顺铂组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Geoffrey I. Shapiro; Raoul Tibes; Michael S. Gordon; Bryan Y. Wong; Joseph Paul Eder; Mitesh J. Borad; David S. Mendelson; Nicholas J. Vogelzang; Bruno R. Bastos; Glen J. Weiss; Cristian Fernandez; William Sutherland; Hitoshi Sato; William E. Pierceall; David Weaver; Scott Slough; Ernesto Wasserman; Donald W. Kufe; Daniel Von Hoff; Takumi Kawabe; Sunil Sharma;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Tetrandrine: A Potent Abrogator of G2 Checkpoint Function in Tumor Cells and Its Mechanism [J] . 生物医学与环境科学（英文版） . 2007,第006期
2. Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. [J] . Shapiro GI, Tibes R, Gordon MS, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第10期

机译：晚期实体瘤患者CBP501（一种G2检查点抑制剂）的I期研究为单一疗法并与顺铂联用。
3. 346 POSTER CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study in patients (pts) with advanced solid tumors [J] . M.S.Gordon, J.P.Eder, D.S.Mendelson, European Journal of Cancer Supplements . 2006,第12期

机译：346 POSTER CBP501，新型细胞周期G2检查点消除剂。晚期实体瘤患者的初始I期和药代动力学（PK）/药效学（PD）研究的初步结果
4. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors [J] . Leijen Suzanne, van Geel Robin M. J. M., Pavlick Anna C., Journal of Clinical Oncology . 2016,第36期

机译：I期研究评估晚期实体瘤患者WEE1抑制剂AZD1775作为单药治疗或与吉西他滨，顺铂或卡铂联用
5. Intralesional Calcium Phosphate/cisplatin Therapy Of Solid Tumors [C] . L. Kuhn, A. Deliso, J. Bordonaro Society for Biomaterials Transactions of the 30th Annual Meeting amp; Exposition vol.28: New Applications and Technologies; 20050427-30; Memphis,TN(US) . 2005

机译：实体瘤内磷酸钙/顺铂疗法
6. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
7. A phase I study of MK-5108 an oral aurora A kinase inhibitor administered both as monotherapy and in combination with docetaxel in patients with advanced or refractory solid tumors [O] . Manik Amin, Susan E. Minton, Patricia M. LoRusso, -1

机译：MK-5108是口服Aurora A激酶抑制剂的I期研究在晚期或难治性实体瘤患者中以单一疗法或与多西他赛联合使用
8. O83 Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors [O] . Ronnie Shapira-Frommer, Marloes GJ van Dongen, Konstantin Dobrenkov, 2020

机译：O83期1研究抗CD27激动剂作为单一疗法，以及患有先进实体肿瘤患者的Pembrolizumab

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

著录项

引文网络

相似文献

相关主题

期刊订阅